News & Updates

[Infographics] STRIDE vs atezolizumab + bevacizumab in 1L HCC – is there any difference in OS

Focusing on dual immunotherapy in unresectable HCC:

• STRIDE (single tremelimumab regular interval durvalumab) is the first and only IO regimen to date with 6-year OS data in unresectable HCC.¹

• In the HIMALAYA study, STRIDE was compared vs sorafenib and achieved a 1.9 times higher 6-year OS rate.¹

• Real-world data indicate that there are no significant differences between STRIDE and atezolizumab + bevacizumab as 1L therapies for advanced HCC, showing them to be equally valid options for patients with advanced HCC.²

Transforming resectable NSCLC care with neoadjuvant/ perioperative IO

Immunotherapy (IO) has shifted the management of resectable non-small-cell lung cancer (NSCLC) towards a multimodality approach that deepens treatment response, resulting in meaningful gains in event‑free survival (EFS) and overall survival (OS). At an industry-sponsored symposium during the 33^rd Annual Scientific Meeting of the Hong Kong College of Radiologists, experts discussed the evidence supporting standard-of-care (SoC) neoadjuvant and perioperative IO in patients with resectable NSCLC, as well as the crucial role of multidisciplinary teams (MDTs) in optimizing treatment outcomes in this population.

Optimizing prostate cancer outcomes with 177Lu-PSMA-617 radioligand therapy

Radioligand therapy, which uses prostate-specific membrane antigen (PSMA)–targeted agents to deliver tumour‑focused radiation, has become a key treatment for metastatic castration‑resistant prostate cancer (mCRPC). At an industry‑sponsored meeting, Professor Kim-Nguyen Chi of the University of British Columbia in Vancouver, Canada, discussed how PSMA-targeted radioligand therapy, specifically lutetium 177–PSMA 617 (¹⁷⁷Lu-PSMA-617), is reshaping mCRPC management and optimizes outcomes.

Complete response to durvalumab consolidation in a patient with unresectable stage III PD-L1–negative NSCLC

A 60-year-old nonsmoking female presented with mild cough in 2023. Apart from hypertension and a history of lung cancer in her father, she was phys­ically fit with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0. 

Managing chronic-phase CML: From intolerance to resistance – clinical experience with asciminib in HK

Case 1: A 78-year-old male with pre-existing comorbidities, including di­abetes, hypertension and ischaemic heart disease (IHD), exemplified the real-world challenges of long-term tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukaemia (CML). Case 2: A 66-year-old male with a long-standing history of CML and failure of multiple TKIs had restored molecular control after switching to a TKI that specifically targets the ABL myristoyl pocket (STAMP).

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

At the European Society for Medical Oncology (ESMO) Asia Congress 2025 in Singapore, results of a retrospective cohort study that evaluated first-line panitumumab- vs cetuximab-based therapy in patients with newly diagnosed RAS wild-type metastatic colorectal cancer (mCRC) were reported. The analysis focused on overall survival (OS) and metastatic-site resection rates, providing valuable real-world insights into treatment selection beyond traditional survival endpoints.

[Infographics] DESTINY-Gastric04: Superior OS with 2L T-DXd in HER2+ metastatic GC/GEJA

As a confirmatory trial building on DESTINY-Gastric02, the phase III DESTINY-Gastric04 trial showed OS benefits with T-DXd vs standard 2L treatment with ramucirumab plus paclitaxel in patients with HER2+ metastatic GC/GEJA, including the Asia subgroup.